Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30827513 | 0.86 | ALDH1A1 (0.78) | ALDH1A1MAPTKMT2ALMNAL3MBTL1 | |
| SCHEMBL1628833 | 0.86 | ALDH1A1 (0.78) | ALDH1A1MAPTKMT2ALMNAL3MBTL1 | |
| SCHEMBL29458655 | 0.85 | ALDH1A1 (0.76) | ALDH1A1MAPTKMT2ALMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL8066446 | 0.85 | ALDH1A1 (0.76) | ALDH1A1MAPTKMT2ALMNAL3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL27461059 | 0.85 | ALDH1A1 (0.76) | ALDH1A1MAPTKMT2ALMNAL3MBTL1 | |
| SCHEMBL3027982 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MAPTKMT2ALMNAL3MBTL1 | |
| SCHEMBL3026613 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MAPTKMT2ALMNAL3MBTL1 | |
| SCHEMBL28089476 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MAPTKMT2ALMNAL3MBTL1 | |
| SCHEMBL13471433 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MAPTKMT2ALMNAL3MBTL1 | |
| SCHEMBL3026611 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MAPTKMT2ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106316931-A | 2-phenyl nicotinic acid derivative with insecticidal/acaricidal activity | 沈阳中化农药化工研发有限公司 | 2017-01-11 | — | — | CN | disclosed |
| CN-106029661-A | Pyrazolo [1,5-A ] pyridine derivatives and methods of use thereof | 亚尼塔公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-105985320-A | Benzylphthalazine compound and its preparation method and use | 复旦大学 | 2016-10-05 | — | — | CN | disclosed |
| CN-101014587-B | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORP | 2013-12-18 | — | — | CN | disclosed |
| CN-103142632-A | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG | 2013-06-12 | — | — | CN | disclosed |
| CN-101370799-B | Cis-4, 5-diaryl-2-heterocycle-imidazolines as MDM2 inhibitors | HOFFMANN LA ROCHE | 2012-09-05 | — | — | CN | disclosed |
| US-8143249-B2 | Prodrugs of A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120003329-A1 | Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension | GILEAD SCIENCES, INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110160162-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7625881-B2 | Prodrugs of A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| CN-101370799-A | Cis-4, 5-diaryl-2-heterocycle-imidazolines as MDM2 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160162-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 651/4885MAPT 4764/4885KMT2A 2662/4885 |
| US-20120003329-A1 | Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension | ADORA2B, ADORA2A, TBXA2R | ALDH1A1 1187/4885MAPT 4874/4885KMT2A 1375/4885 |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 908/4885MAPT 4779/4885KMT2A 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.